美国FDA认定Celliant(R)功能性纺织品符合医疗器械和一般健康产品标准

2017-07-28 佚名 MedSci原创

Hologenix, LLC的技术是获得FDA共同认可的同类首个技术 

Celliant工程产品经临床证明能够促进人体局部血流增加

FDA的决定将迎来功能性织物与纺织品的新时代

洛杉矶2017年7月25日电 /美通社/ -- 世界上最先进的、经临床证明的功能性纺织品技术Celliant的制作公司Hologenix, LLC今天宣布,美国食品药品管理局(FDA)已经认定Celliant产品属于《联邦食品、药品和化妆品法案》(Federal Food, Drug and, Cosmetic Act)第201(h)节界定的医疗器械和一般健康产品。FDA表示,Celliant被认定为医疗器械是因为用于健康个体时,能够暂时促进应用部位的血流增加。

“PureCare Elements: Lumen® Premium Celliant® Sheet Set: 采用Celliant来增加舒适性和促进睡眠时快速恢复的首个亚麻系列。”
“PureCare Elements: Lumen® Premium Celliant® Sheet Set: 采用Celliant来增加舒适性和促进睡眠时快速恢复的首个亚麻系列。”

 

“SIMA获奖产品Xcel Infinity Comp TDC Full Suit with Celliant:采用Celliant打造温暖的潜水衣衬,从而帮助您冲浪更久、恢复更快。”
“SIMA获奖产品Xcel Infinity Comp TDC Full Suit with Celliant:采用Celliant打造温暖的潜水衣衬,从而帮助您冲浪更久、恢复更快。”

 

“ISPO获奖产品Tecnica Mach 1 Pro Women Ski Boot:一款女性为女性打造的滑雪靴,里衬采用Celliant和Imbotex的Lambswool Heat,满足女性上下斜坡时对温暖、舒适和性能的特殊需求。上市时间:2017年秋季;
“ISPO获奖产品Tecnica Mach 1 Pro Women Ski Boot:一款女性为女性打造的滑雪靴,里衬采用Celliant和Imbotex的Lambswool Heat,满足女性上下斜坡时对温暖、舒适和性能的特殊需求。上市时间:2017年秋季;

 

“Salewa Puez TirolWool Celliant Half Zip Jacket:混合了Imbotex的自然保暖,透气和疏水绝缘的TirolWool与Celliant,来帮助户外运动爱好者整天保持精力充沛和温暖。上市时间:2017年秋季”
“Salewa Puez TirolWool Celliant Half Zip Jacket:混合了Imbotex的自然保暖,透气和疏水绝缘的TirolWool与Celliant,来帮助户外运动爱好者整天保持精力充沛和温暖。上市时间:2017年秋季”

Hologenix首席执行官Seth Casden表示:“Celliant工程产品是同类首个被FDA认可为医疗器械的产品。我们的技术可用于日常产品——T恤、衣服、床上用品,甚至飞机座椅 -- 以增加局部血液流动,从而增加力量、提高运动效果和加速肌肉恢复。”

Casden表示:“我们认为Celliant是一个改变纺织品应用的真正颠覆性技术。我们目前正在评估Celliant在医疗领域的更多应用,例如,身体组织血流增加可能会让糖尿病患者受益。”

Celliant工程产品利用和回收人类排放的自然热量,从而提高运动效果,并且帮助人们在体育运动后和睡眠时恢复和补充体力。Celliant由植入到用于制造各类纺织品和织物的纤维核心内部的多种热活性矿物质经过获得专利的技术混合而成,因此不会被洗掉或者磨坏。由Celliant织物制成的产品吸收身体的热量,并将其转换成红外能量(IR),再以安全、自然的方式循环到皮肤和组织中。IR是一种血管扩张剂,能增加全身组织和肌肉的血液流动,为细胞提供重要的营养和氧气。这种效果经临床证明,能够帮助身体:

  • 增加力量、耐力、体力和运动效果
  • 体育活动之后恢复更快
  • 促进睡眠和增加舒适度

Celliant广泛用于各种纺织品和应用中 -- 服装、床上用品、雨衣和兽药产品,包括:

  • SIMA获奖产品Xcel Infinity Comp TDC Full Suit with Celliant,采用Celliant打造温暖的潜水衣衬,从而帮助您冲浪更久、恢复更快;
  • Salewa Puez TirolWool Celliant Half Zip Jacket,混合了Imbotex的自然保暖,透气和疏水绝缘的TirolWool与Celliant,来帮助户外运动爱好者整天保持精力充沛和温暖。上市时间:2017年秋季;
  • ISPO获奖产品Tecnica Mach 1 Pro Women Ski Boot,一款女性为女性打造的滑雪靴,里衬采用 Celliant和Imbotex的Lambswool Heat,满足女性上下斜坡时对温暖、舒适和性能的特殊需求。上市时间:2017年秋季;
  • PureCare Elements: Lumen® Premium Celliant® Sheet Set,这是采用Celliant来增加舒适性和促进睡眠时快速恢复的首个亚麻系列。

马萨诸塞总医院韦尔曼光医学中心首席调查员Michael R Hamblin博士表示:“科学研究表明,红外能量能够增加血液流动、改善肌肉恢复和减轻长期疼痛。FDA将Celliant产品认定为医疗器械和一般健康产品将有望刺激人们对红外技术的兴趣以及能够造福人民的服装和包装的进一步发展。”

Celliant已经经过广泛的研究与开发以及耐久性和有效性临床试验。多家知名机构进行了九项临床试验来评估Celliant的效果,包括加州大学欧文分校(University of California Irvine)、卡尔加里大学(University of Calgary)、UCI Long Beach Veterans Affairs Medical Center、德克萨斯A&M大学(Texas A&M University)、芝加哥洛约拉大学(Loyola University Chicago)和Exponent。实验证明,Celliant技术能够将应用部位的组织氧水平提高8%i。点击这里查看美国国立卫生研究院(NIH)针对IR给身体恢复带来的好处的独立研究。

iIan Gordon博士 -- 加州大学欧文分校,《Effect of Garment with 42% Celliant Fiber on TCP02 Levels and Grip Strength in Healthy Subjects》。2010年

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1870082, encodeId=da3a18e00821e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Sep 20 05:34:00 CST 2017, time=2017-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960342, encodeId=9b0b1960342ab, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Mar 23 12:34:00 CST 2018, time=2018-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804679, encodeId=7f4818046e9fa, content=<a href='/topic/show?id=6241e7536dd' target=_blank style='color:#2F92EE;'>#纺织品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77536, encryptionId=6241e7536dd, topicName=纺织品)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e43278, createdName=yangjxjc, createdTime=Wed Sep 13 09:34:00 CST 2017, time=2017-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915434, encodeId=9647191543419, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Sat Aug 12 00:34:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551396, encodeId=e5b315513968d, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Jul 30 02:34:00 CST 2017, time=2017-07-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1870082, encodeId=da3a18e00821e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Sep 20 05:34:00 CST 2017, time=2017-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960342, encodeId=9b0b1960342ab, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Mar 23 12:34:00 CST 2018, time=2018-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804679, encodeId=7f4818046e9fa, content=<a href='/topic/show?id=6241e7536dd' target=_blank style='color:#2F92EE;'>#纺织品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77536, encryptionId=6241e7536dd, topicName=纺织品)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e43278, createdName=yangjxjc, createdTime=Wed Sep 13 09:34:00 CST 2017, time=2017-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915434, encodeId=9647191543419, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Sat Aug 12 00:34:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551396, encodeId=e5b315513968d, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Jul 30 02:34:00 CST 2017, time=2017-07-30, status=1, ipAttribution=)]
    2018-03-23 维他命
  3. [GetPortalCommentsPageByObjectIdResponse(id=1870082, encodeId=da3a18e00821e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Sep 20 05:34:00 CST 2017, time=2017-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960342, encodeId=9b0b1960342ab, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Mar 23 12:34:00 CST 2018, time=2018-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804679, encodeId=7f4818046e9fa, content=<a href='/topic/show?id=6241e7536dd' target=_blank style='color:#2F92EE;'>#纺织品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77536, encryptionId=6241e7536dd, topicName=纺织品)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e43278, createdName=yangjxjc, createdTime=Wed Sep 13 09:34:00 CST 2017, time=2017-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915434, encodeId=9647191543419, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Sat Aug 12 00:34:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551396, encodeId=e5b315513968d, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Jul 30 02:34:00 CST 2017, time=2017-07-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1870082, encodeId=da3a18e00821e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Sep 20 05:34:00 CST 2017, time=2017-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960342, encodeId=9b0b1960342ab, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Mar 23 12:34:00 CST 2018, time=2018-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804679, encodeId=7f4818046e9fa, content=<a href='/topic/show?id=6241e7536dd' target=_blank style='color:#2F92EE;'>#纺织品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77536, encryptionId=6241e7536dd, topicName=纺织品)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e43278, createdName=yangjxjc, createdTime=Wed Sep 13 09:34:00 CST 2017, time=2017-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915434, encodeId=9647191543419, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Sat Aug 12 00:34:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551396, encodeId=e5b315513968d, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Jul 30 02:34:00 CST 2017, time=2017-07-30, status=1, ipAttribution=)]
    2017-08-12 xlxchina
  5. [GetPortalCommentsPageByObjectIdResponse(id=1870082, encodeId=da3a18e00821e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Sep 20 05:34:00 CST 2017, time=2017-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960342, encodeId=9b0b1960342ab, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Mar 23 12:34:00 CST 2018, time=2018-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804679, encodeId=7f4818046e9fa, content=<a href='/topic/show?id=6241e7536dd' target=_blank style='color:#2F92EE;'>#纺织品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77536, encryptionId=6241e7536dd, topicName=纺织品)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e43278, createdName=yangjxjc, createdTime=Wed Sep 13 09:34:00 CST 2017, time=2017-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915434, encodeId=9647191543419, content=<a href='/topic/show?id=22a1328e7e5' target=_blank style='color:#2F92EE;'>#功能性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32877, encryptionId=22a1328e7e5, topicName=功能性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Sat Aug 12 00:34:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551396, encodeId=e5b315513968d, content=<a href='/topic/show?id=5d84e9716c0' target=_blank style='color:#2F92EE;'>#美国FDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79716, encryptionId=5d84e9716c0, topicName=美国FDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Jul 30 02:34:00 CST 2017, time=2017-07-30, status=1, ipAttribution=)]

相关资讯

丰盛榜携健身教练挑战小蛮腰,助力丰字腹行动

/* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li

全口服直接抗丙肝病毒治疗方案正式在中国上市

/* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnew

“喂”爱坚守,不止于你 -- 雀巢举办系列活动倡议母乳喂养

/* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_